Caxton Associates (New York)’s Gritstone bio, Inc. Common Stock GRTS Stock Holding History

Caxton Associates (New York)’s Portfolio GRTS Stock Details GRTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-87,786	Closed	-$244K	–	684
2023 Q1	$244K	Sell	87,786 -32,348	-27%	-$92.4K	0.04%	386
2022 Q4	$414K	Buy	120,134 +24,944	+26%	+$71.2K	0.03%	273
2022 Q3	$245K	Buy	+95,190	New	+$303K	0.03%	362
2022 Q1	–	Sell	-13,797	Closed	-$177K	–	752
2021 Q4	$177K	Buy	+13,797	New	+$153K	0.02%	502

Other funds holding GRTS

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caxton Associates (New York)'s GRTS Position: Q2 2023 in Review

Caxton Associates (New York) sold out of Gritstone bio, Inc. Common Stock (GRTS) in Q2 2023, closing a stake of 87,786 shares — an estimated $244K sold.

Caxton Associates (New York) first reported a position in GRTS in Q4 2021 and held it in 4 quarters. The position peaked at $414K in Q4 2022. 88 funds tracked by Wall St. Rank hold GRTS as of Q2 2023.

Caxton Associates (New York) reported no remaining Gritstone bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Caxton Associates (New York) sold 87,786 Gritstone bio, Inc. Common Stock shares in Q2 2023, an estimated $244K.
Caxton Associates (New York) first reported a position in Gritstone bio, Inc. Common Stock in Q4 2021 and held it in 4 quarters.
Caxton Associates (New York)'s Gritstone bio, Inc. Common Stock position peaked at $414K in Q4 2022.
88 funds tracked by Wall St. Rank held Gritstone bio, Inc. Common Stock as of Q2 2023.

Based on Caxton Associates (New York)'s 13F filing for Q2 2023, filed 15 Aug 2023.